Saturday 17 October 2026
Export ESTA’s income statement to Excel — free account
Establishment Labs Holdings Inc.
ESTA Healthcare Medical Devices
Establishment Labs Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $211.1 million, up 27.1% from fiscal 2024. In the quarter to June 2026, revenue grew 31.7%, EPS grew 31.6%, free cash flow grew 2.75% and total debt rose 18.3%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
59.18
2.18
−3.55%
Follow ESTA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
6.36 | 10.23 | 7.41 | 10.52 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(107.93) | (13,325.34) | (394.52) | (155.69) | |
P/B ratio |
74.20 | 91.68 | 115.02 | 119.63 | |
Price to Tangible BV |
255.35 | 174.15 | 398.12 | 235.66 | |
EV/Sales |
7.39 | 11.14 | 8.29 | 11.38 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(19.75) | (46.22) | (55.18) | (86.52) | |
EV/FCF |
(18.02) | (40.82) | (45.15) | (67.30) | |
Quick Ratio |
1.97 | 1.86 | 1.75 | 2.27 | |
Current Ratio |
3.33 | 3.04 | 2.96 | 3.84 | |
Net Debt/EBITDA |
(118.57) | (148.23) | (47.26) | (117.48) | |
Debt/Assets |
72.72% | 69.30% | 70.82% | 74.36% | |
Debt/Equity |
15.06 | 10.51 | 16.82 | 12.11 | |
Asset Turnover |
0.61 | 0.60 | 0.67 | 0.72 | |
Operating CF/Net income |
1.01 | 0.06 | 0.32 | 1.41 | |
Capex/Depreciation |
(0.77) | (0.60) | (0.73) | (1.37) | |
Interest Coverage |
(0.65) | (0.54) | (0.92) | (0.61) | |
Research and Development Expense of Revenue |
8.47% | 8.41% | 8.75% | 7.54% | |
Selling, General and Administrative Expense of Revenue |
69.10% | 68.14% | 72.82% | 69.45% | |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
5.56% | 4.64% | 5.18% | 4.64% | |
Graham Net Nets |
(0.07) | (0.04) | (0.05) | (0.03) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(6.93%) | (2.39%) | (2.62%) | (1.53%) | |
Free Cash Flow Yield |
(6.45%) | (2.67%) | (2.48%) | (1.61%) | |
Revenue per Share |
1.82 | 2.18 | 2.00 | 2.24 | |
Operating CF per Share |
(0.38) | (0.01) | (0.14) | (0.55) | |
Capex per Share |
(0.07) | (0.06) | (0.07) | (0.12) | |
Free Cash Flow per Share |
(0.45) | (0.06) | (0.21) | (0.67) | |
Cash per Share |
2.38 | 2.55 | 2.27 | 2.36 | |
Shareholders Equity per Share |
0.55 | 0.80 | 0.49 | 0.72 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.55 | 0.80 | 0.49 | 0.72 | |
Free Cash Flow |
(13.21) | (1.82) | (6.27) | (20.25) | |
Working Capital |
167.62 | 167.80 | 162.67 | 183.17 | |
Capital Expenditures |
(1.96) | (1.66) | (1.96) | (3.65) | |
Net Current Asset Value |
(82.93) | (83.68) | (90.43) | (82.59) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.03 | 0.03 | 0.05 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
69.35 | 71.25 | 70.16 | 72.87 | |
Average Payables |
37.06 | 43.93 | 43.50 | 44.32 | |
Average Inventory |
77.64 | 82.19 | 88.54 | 89.83 | |
Average Assets |
310.79 | 352.00 | 342.20 | 340.80 | |
Average Common Equity |
24.54 | 38.32 | 26.67 | 22.19 |
Columns are period end dates